Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,424.85 162.29 1.00%
S&P 500 1,862.31 19.33 1.05%
NASDAQ 4,086.22 52.06 1.29%
Ticker Volume Price Price Delta
STOXX 50 3,139.26 47.74 1.54%
FTSE 100 6,584.17 42.56 0.65%
DAX 9,317.82 144.11 1.57%
Ticker Volume Price Price Delta
NIKKEI 14,364.55 -53.13 -0.37%
TOPIX 1,163.11 -3.44 -0.29%
HANG SENG 22,754.74 58.73 0.26%

Ligand to Report First Quarter Results on May 8th



  Ligand to Report First Quarter Results on May 8th

Business Wire

SAN DIEGO -- April 22, 2013

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced today plans to
report first quarter 2013 financial results on Wednesday, May 8, 2013.
Ligand’s President and CEO, John Higgins, Executive Vice President and COO,
Matt Foehr and Vice President of Finance and CFO, John Sharp will host the
conference call.

First Quarter Earnings Call

                          
                           Ligand Pharmaceuticals conference call to discuss
What:                      financial results and provide general business
                           updates.
 
When:                      Wednesday, May 8, 2013
 
Time:                      1:30 p.m. Pacific time (4:30 p.m. Eastern time)
 
Webcast:                   Conference call and replay accessible at
                           www.ligand.com
 
Conference Call:           (877) 407-4019, passcode: Ligand
                           (201) 689-8337 outside the U.S.
 
Replay:                    (877) 660-6853, passcode: 396983
                           (201) 612-7415 outside the U.S.
                            

About Ligand Pharmaceuticals

Ligand is a biopharmaceutical company that develops and acquires assets it
believes will generate royalty revenues and, under its lean corporate cost
structure, produce sustainable profitability. Ligand has a diverse asset
portfolio addressing the unmet medical needs of patients for a broad spectrum
of diseases including thrombocytopenia, multiple myeloma, diabetes, hepatitis,
muscle wasting, dyslipidemia, anemia and osteoporosis. Ligand’s Captisol
platform technology is a patent-protected, chemically modified cyclodextrin
with a structure designed to optimize the solubility and stability of drugs.
Ligand has established multiple alliances with the world's leading
pharmaceutical companies including GlaxoSmithKline, Onyx Pharmaceuticals,
Merck, Pfizer, Baxter International, Bristol-Myers Squibb, Celgene, Lundbeck
Inc., Eli Lilly & Co., Spectrum Pharmaceuticals and The Medicines Company.
Please visit www.captisol.com for more information on Captisol or
www.ligand.com for more information on Ligand.

Follow Ligand on Twitter @Ligand_LGND.

Contact:

Ligand Pharmaceuticals Incorporated
John Higgins, President and CEO
Jennifer Capuzelo, Investor Relations
jcapuzelo@ligand.com
(858) 550-7584
or
LHA
Don Markley
dmarkley@lhai.com
(310) 691-7100
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement